Clinical Trials
59 trialsHyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant
University of Rochester
ALERTCML
University of Alabama at Birmingham
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML
M.D. Anderson Cancer Center
HALTAging-1
University of Nebraska
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation
Stanford University
CIML NK Cells With Venetoclax for AML
Dana-Farber Cancer Institute
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
M.D. Anderson Cancer Center
GAVEL
Dana-Farber Cancer Institute
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
University of Colorado, Denver
Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Dana-Farber Cancer Institute
IAMFIT
Children's Hospital of Philadelphia
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT
Peking University People's Hospital
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
University of Pittsburgh
The Role and Mechanism of TCR-T Cells in Immunotherapy for Acute Myeloid Leukemia
Shenzhen University General Hospital
Autologous Hematopoietic Cell Transplantation for Core-binding Factor Acute Myeloid Leukemia
Asan Medical Center
Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy
Affiliated Hospital of Nantong University
FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia
Masonic Cancer Center, University of Minnesota
Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients
Virginia Commonwealth University
FluBuATG
Dartmouth-Hitchcock Medical Center
AC220 for Children With Relapsed/Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Family Caregiver Ambassador Support for Family Caregivers of Patients With Hematological Disease
Rigshospitalet, Denmark
PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
University of Colorado, Denver
A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Therapeutic Advances in Childhood Leukemia Consortium
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
Hospital Universitario 12 de Octubre
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
Barbara Ann Karmanos Cancer Institute
NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents
Instituto de Investigación Hospital Universitario La Paz
A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML
Nanfang Hospital, Southern Medical University
UF-BMT-MRD-101
University of Florida
Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation
University of Wisconsin, Madison
Biobehavioral Intervention to Enhance Hematopoietic Stem Cell Transplant Recovery
University of Wisconsin, Madison
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Stanford University
UPCC 02407
Abramson Cancer Center at Penn Medicine
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Stanford University
Clofarabine Plus Cytarabine in Patients With Previously Untreated Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)
M.D. Anderson Cancer Center
TBF-Cord
Assistance Publique - Hôpitaux de Paris
Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia
Stanford University
Cyclophosphamide and Busulfan as Conditioning Regimen Before Allogeneic HSCT
University Hospital, Basel, Switzerland
Donor-derived Anti-CD123-CART Cells for Recurred AML After Allo-HSCT
Affiliated Hospital to Academy of Military Medical Sciences
High Dose Donor Hematopoietic Stem Cell Infusion for Relapsed/Refractory AML
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Granulocyte-colony Stimulating Factor (G-CSF) and Plerixafor Plus Sorafenib for Acute Myelogenous Leukemia (AML) With FLT3 Mutations
M.D. Anderson Cancer Center
Test Extracorporeal Photopheresis (ECP) Treatment Before/After Allogeneic Bone Marrow Transplant (BMT) or Peripheral Blood Stem Cell (PBSC) Transplant to Prevent Graft Versus Host Disease
University of Kansas Medical Center
Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia
University of Massachusetts, Worcester
Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus
Massachusetts General Hospital